Comparison of Gallium - 68 Prostate-Specific Membrane Antigen (Ga-68 PSMA) normal tissue uptake across tumor burden groups among Filipino patients with prostate cancer
- Author:
Mary Stephanie Jo C. Estrada
1
;
Eduardo Erasto S. Ongkeko
1
;
Mia Anne Ryna L. Bayot
1
;
Kalvin B. Catubao
1
;
Klein Reagan R. Bautista
1
;
Patricia A. Bautista - Penalosa
1
Author Information
1. Division of Nuclear Medicine and PET Center, St. Lukes Medical Center - Global City
- Publication Type:Journal Article
- Keywords:
Prostate-specific membrane antigen;
Ga-68 PSMA I&T;
PET/CT;
Biodistribution
- MeSH:
Positron-Emission Tomography;
Prostatic Neoplasms;
Tumor Burden
- From:
The Philippine Journal of Nuclear Medicine
2021;16(2):26-36
- CountryPhilippines
- Language:English
-
Abstract:
Background:PSMA-targeted radiopharmaceuticals have been widely studied for their theragnostic role in prostate cancer
and were introduced in the Philippines in 2018. The optimal administered activity of 177Lu-PSMA for targeted
endoradiotherapy has not yet been established and is thought to be influenced by several factors, including
tumor burden. This study investigates the effect of tumor burden on the normal tissue PSMA uptake among
Filipino patients with prostate cancer using its diagnostic counterpart, 68Ga-PSMA I&T
Methods:One hundred four patients imaged with 68Ga-PSMA I&T PET/CT in our institution from January 2018 to May
2020 were included. Patients were visually classified into low, medium, and high tumor burden groups.
Maximum and mean standardized uptake values (SUVmax and SUVmean) of the lacrimal glands, parotid
glands, submandibular glands, kidneys, liver, spleen, and bone were measured and compared among tumor
burden groups.
Results and Conclusions:68Ga-PSMA I&T uptake in the kidneys, the salivary glands, and the liver, were significantly reduced by
approximately 25-50% in patients with high tumor burden. This finding supports the hypothesis that patients
with higher tumor load can tolerate higher activity doses of 177Lu-PSMA for endoradiotherapy before developing
significant damage to the critical organs. This may serve as a guide towards optimizing and personalizing
177Lu-PSMA I&T administered activity dose for radionuclide therapy
- Full text:Comparison of Gallium.pdf
